Merck invests in innovation to provide patients with new medicines and to improve current ones. A thoughtful approach to intellectual property is needed.
In the context of this approach, Merck supports the TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) frameworks, including the Doha declaration and Article 31f and refrains from filing any patent applications relating to pharmaceuticals in Least Developed Countries (LDCs).
We believe that patent pools can be a suitable method to develop and market products. Therefore, Merck has no general objections to join patent pools, under appropriate conditions, in particular for the development of drugs for neglected diseases.
Also, we believe that voluntary licensing can be an appropriate tool to improve access to medicines. Merck will consider opportunities for non-exclusive voluntary licensing providing fair and reasonable compensation for all interested parties, particularly to increase access and affordability of products in LDCs.
